Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes—A retrospective single‐centre review of real‐world data
Author:
Affiliation:
1. Department of Dermatology Royal Victoria Infirmary Newcastle upon Tyne UK
2. Translational and Clinical Research Institute (Dermatology) Newcastle University Newcastle upon Tyne UK
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18623
Reference6 articles.
1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
2. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
3. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
4. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study
5. Key findings towards optimising adalimumab treatment: the concentration–effect curve
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Improving the Accuracy of Biologic Drug Survival Data: The Increasing Prevalence of Off-Label Dosing Must Be Considered when Reporting Drug Effectiveness and Safety;Journal of Investigative Dermatology;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3